China's New Hope: Center Fights Rare Cancer with Breakthrough Drug

BOAO, China – January 29, 2026 – In a significant development for rare disease treatment, the International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital, offering a dedicated new front against one of oncology's most formidable challenges. This specialized center, born from a strategic collaboration between the hospital and Chongqing University Three Gorges Hospital, aims to rewrite the narrative for patients with NUT carcinoma, an aggressive cancer with a historically grim prognosis.

At the heart of this initiative is NHWD-870, a landmark oral medication developed by Chinese biotech firm Zhejiang Wenda Pharma Technology Co., Ltd. The center leverages a unique policy environment to provide access to this promising new therapy, creating a powerful nexus of clinical expertise, pharmaceutical innovation, and accelerated patient care.

A Formidable and Underdiagnosed Foe

NUT (Nuclear Protein in Testis) carcinoma is a rare and devastating malignancy defined by its rapid progression and profound resistance to conventional treatments. The disease is notoriously difficult to diagnose, often leading to delays that can be critical given its aggressive nature. While it can affect individuals of any age, it disproportionately strikes adolescents and young adults, with a median age of onset between 18 and 23 years.

For decades, patients have faced a stark reality: a lack of a standard-of-care treatment and a median overall survival rate hovering between six and ten months. Traditional approaches like surgery, radiation, and chemotherapy have shown limited and rarely durable success, highlighting what medical experts describe as a profound "unmet medical need."

"Our mission is to light a definitive beacon of hope," said Professor YIN Mingzhu, a key leader of the new center. "We are here to ensure every patient has access to advanced, life-extending care."

The center's establishment builds upon a deep well of experience. Chongqing University Three Gorges Hospital is a national pioneer, having previously established China's first dedicated NUT carcinoma clinic. That institution has treated over 200 patients from across the country and spearheaded the development of the nation's first expert consensus on diagnosing and managing the disease, creating a foundation of specialized knowledge that is now centralized in Boao.

The Promise of a Homegrown Breakthrough

The central weapon in the new center's arsenal is NHWD-870. It is the world's first and only oral BET inhibitor specifically targeting advanced NUT carcinoma. BET inhibitors are a class of drugs designed to interfere with bromodomain and extraterminal domain (BET) proteins, which are crucial for reading genetic information that drives tumor growth. In NUT carcinoma, a genetic fusion creates a BRD4-NUT oncoprotein that makes the cancer cells addicted to this pathway, providing a clear target for drugs like NHWD-870.

Clinical data for the drug has been promising. Trials have shown an objective response rate of 33.3%—meaning a third of patients saw their tumors shrink significantly—and a disease control rate of 73.33%. More importantly, the drug has extended the median overall survival to 9.3 months in trial settings. Real-world studies emerging from its early use have reported an even more encouraging one-year survival rate of 54.7%, a dramatic improvement for this patient population.

Beyond statistics, individual results have been striking. A peer-reviewed case report from 2025 detailed a 36-year-old patient with advanced pulmonary NUT carcinoma who achieved a pathological complete response—no detectable cancer cells—within five months of starting NHWD-870 monotherapy. While independent oncologists caution that BET inhibitors can have limitations and that resistance can develop, they agree that the therapy is a promising and logical approach for this genetically defined cancer. Many see the future in using these drugs as a backbone for combination therapies, a research area the new center is poised to lead.

A Unique Model of Innovation and Access

The center’s ability to offer this cutting-edge treatment is made possible by its strategic location within the Boao Hope Pilot Zone of International Medical Tourism. This special economic and policy zone on Hainan Island operates under a unique "Four Special Permissions" policy. This framework is designed to slash red tape and accelerate the clinical use of innovative medical products and technologies that have not yet received full national approval in China.

This policy allows the Boao center to function as a vital gateway, providing Chinese patients with access to global innovations and, in this case, fast-tracking a domestic breakthrough like NHWD-870 into clinical practice. The zone has already introduced over 540 innovative therapies, transforming it into a "Hope City" for patients seeking treatments unavailable elsewhere in the country.

This model not only accelerates patient access but also creates an unparalleled environment for clinical research. By concentrating patients, experts, and novel therapies in one location, the center will generate crucial real-world evidence on the efficacy and management of NHWD-870. This data, gathered through a concurrently launched research and innovation platform, is expected to shape future global treatment standards for NUT carcinoma and potentially other rare diseases.

A Collaborative Blueprint for Rare Disease Care

The launch of the International NUT Carcinoma Diagnosis and Treatment Center represents more than just a new building or a new drug; it signifies a new, integrated model for tackling rare diseases. The initiative masterfully combines the deep clinical expertise of a pioneering national hospital, the targeted innovation of a domestic biopharma company, and the enabling power of a forward-thinking government policy.

This collaborative approach is seen by public health experts as a potential blueprint for addressing other rare and neglected diseases that often fall through the cracks of traditional healthcare and pharmaceutical development pipelines. By creating a self-sustaining ecosystem of care and research, the center aims to not only improve outcomes for its current patients but also to build a foundation of knowledge that will benefit patients for years to come.

With the launch of the International NUT Carcinoma Registry, the center is also making a global call for collaboration, inviting researchers and clinicians worldwide to contribute to a shared understanding of the disease. For the small but global community of patients and families affected by NUT carcinoma, the new center in Boao represents the most tangible source of hope in a generation.